Biotinylated Human HLA-A*02:01&B2M&SSX-2 (KASEKIFYV) Complex Protein (Monomer, MALS verified)

Product Number/Spec
Price
Availability
Menge
HL2-H82Es-25ug
$125.00
In Stock - Delivery in 1-2 business days
HL2-H82Es-200ug
$700.00
In Stock - Delivery in 2 weeks
HL2-H82Es
Product Amount :
$ 0
0
Add to Cart
New Product Suggestion Request Quote
Contact Us
Contact Us
Product Amount:
$ 0
0
Add to Cart
  • Product Details
  • Data Display
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

HLA-A*0201 & B2M & SSX-2 (KASEKIFYV)

Source

Biotinylated Human HLA-A*02:01&B2M&SSX-2 (KASEKIFYV) Complex Protein (HL2-H82Es) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & KASEKIFYV peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769-1 (B2M) & KASEKIFYV).

Predicted N-terminus: Gly 25 & Ile 21

Molecular Characterization

Biotinylated Human HLA-A*02:01&B2M&SSX-2 (KASEKIFYV) Complex Protein is produced by co-expression of HLA and B2M loaded with SSX-2 peptide.

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 40-43 kDa and 11 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Purity

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Background Introduction

The peptide KASEKIFYV, derived from the cancer-testis antigen SSX-2, is presented by the HLA-A*02:01/β2-microglobulin (β2m) complex. This peptide-MHC complex is recognized as a tumor-associated antigen and can elicit specific cytotoxic T lymphocyte (CTL) responses. Its presentation on certain tumor cells makes it a potential target for cancer immunotherapy, particularly in cancers where SSX-2 is aberrantly expressed, such as melanoma, synovial sarcoma, and some carcinomas.